Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

@article{Arechavaleta2011EfficacyAS,
  title={Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.},
  author={Rosario Arechavaleta and Thomas L Seck and Yingli Chen and Karl J. Krobot and Edward A O'neill and L Duran and Keith L. Kaufman and Debora E Williams-Herman and Barry J. Goldstein},
  journal={Diabetes, obesity & metabolism},
  year={2011},
  volume={13 2},
  pages={
          160-8
        }
}
AIM to evaluate the efficacy and safety of adding sitagliptin or glimepiride to the treatment regimen of patients with type 2 diabetes mellitus and inadequate glycaemic control on metformin monotherapy. METHODS patients with type 2 diabetes and an HbA(1c) of 6.5-9.0% while on a stable dose of metformin (≥ 1500 mg/day) combined with diet and exercise for at least 12 weeks were randomized in a double-blind manner to receive either sitagliptin 100 mg daily (N = 516) or glimepiride (starting dose… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 86 CITATIONS, ESTIMATED 41% COVERAGE

Sitagliptin/Metformin Fixed-Dose Combination

VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Sitagliptin: A Review in Type 2 Diabetes

VIEW 4 EXCERPTS
HIGHLY INFLUENCED

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

VIEW 4 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 6 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Comparative analysis of two rates.

  • Statistics in medicine
  • 1985
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes

R Brazg, L Xu, +3 authors PP. Stein
  • Diabetes Obes Metab
  • 2007